Preview

Научно-практическая ревматология

Расширенный поиск

Роль биомаркеров в диагностике бактериальных инфекций при ревматических заболеваниях

https://doi.org/10.14412/1995-4484-2019-333-338

Полный текст:

Аннотация

В современной ревматологии проблема дифференциальной диагностики бактериальной инфекции и активного ревматического процесса по-прежнему сохраняет свою актуальность. При этом весьма важен вопрос поиска биомаркера – «золотого стандарта» диагностики инфекции у пациентов с ревматическими заболеваниями (РЗ) в целях быстрого определения тактики лечения. В настоящем обзоре проанализированы диагностическая значимость и возможность применения некоторых лабораторных маркеров бактериальных инфекций в современной ревматологии. Подчеркивается важность мультимаркерного подхода, позволяющего увеличить значимость отдельных параметров в диагностике инфекций при РЗ.

Об авторах

Б. С. Белов
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

115522, Москва, Каширское шоссе, 34А.



Г. М. Тарасова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А.


Н. В. Муравьева
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А.


Список литературы

1. Белобородова НВ, Попов ДА. Тест на прокальцитонин: алгоритмы применения и новые возможности. Пособие для врачей. Москва; 2008. 74 с. [Beloborodova NV, Popov DA. Test na prokal'citonin: algoritmy primeneniya i novye vozmozhnosti. Posobie dlya vrachey [Procalcitonin test: application algorithms and new features. Manual for doctors]. Moscow; 2008.74 p. (In Russ.)].

2. Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta. 2002;323(1-2):17-29. doi: 10.1016/S0009-8981(02)00101-8

3. Paosong S, Narongroeknawin P, Pakchotanon R, et al. Serum procalcitonin as a diagnostic aid in patients with acute bacterial septic arthritis. Int J Rheum Dis. 2015;18(3):352-9. doi: 10.1111/1756-185X.12496

4. Shen CJ, Wu MS, Lin KH, et al. The use of procalcitonin in the diagnosis of bone and joint infection: a systemic review and metaanalysis. Eur J Clin Microbiol Infect Dis. 2013;32(6):807-14. doi: 10.1007/s10096-012-1812-6

5. Choi ST, Song JS. Serum Procalcitonin as a Useful Serologic Marker for Differential Diagnosis between Acute Gouty Attack and Bacterial Infection. Yonsei Med J. 2016;57(5):1139-44. doi: 10.3349/ymj.2016.57.5.1139

6. Zhang J, Zhao C, Wu T, et al. Procalcitonin may not be a differential diagnostic marker for bacterial infection in febrile patients with chronic gouty arthritis. J Int Med Res. 2018;46(10):4197-206. doi: 10.1177/0300060518791093

7. Wu JY, Lee SH, Shen CJ, et al. Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and metaanalysis. Arthritis Rheum. 2012;64(9):3034-42. doi: 10.1002/art.34512

8. Лапин СВ, Маслянский АЛ, Лазарева НМ и др. Значение количественного определения прокальцитонина для диагностики септических осложнений у больных с аутоиммунными ревматическими заболеваниями. Клиническая лабораторная диагностика. 2013;(1):28-33 [Lapin SV, Maslyanskiy AL, Lazareva NM, et al. The value of quantitative analysis of procalcitonine in diagnostics of septic complications in patients with autoimmune rheumatic diseases. Klinicheskaya Laboratornaya Diagnostika. 2013;(1):28-33 (In Russ.)].

9. Тарасова ГМ, Белов Б.С, Дилбарян АГ, и др. Значение определения сывороточного прокальцитонина в дифференциальной диагностике инфекций и ревматических заболеваний. Медицинский совет. 2018;18:86-91 [Tarasova GM, Belov BS, Dilbaryan AG, et al. The value of determining serum procalcitonin in the differential diagnosis of infections and rheumatic diseases. Medicinskiy Sovet. 2018;18:86-91 (In Russ.)]. doi: 10.21518/2079-701X-2018-18-86-91

10. Ho W-L, Lan J-L, Chen D-Y, et al. Procalcitonin may be a potential biomarker for distinguishing bacterial infection from disease activity in febrile patients with systemic lupus erythematosus. Formosan J Rheumatol. 2009;23:52-8. doi: 10.1007/s10067-015-3020-0

11. Shin KC, Lee YJ, Kang SW, et al. Serum procalcitonin measurement for detection of intercurrent infection in febrile patients with SLE. Ann Rheum Dis. 2001;60(10):988-9. doi: 10.1136/ard.60.10.988

12. Liu LN, Wang P, Guan SY, et al. Comparison of plasma/serum levels of procalcitonin between infection and febrile disease flare in patients with systemic lupus erythematosus: a meta-analysis. Rheumatol Int. 2017;37(12):1991-8. doi: 10.1007/s00296-017-3827-x

13. El-Serougy E, Zayed HS, Ibrahim NM, Maged LA. Procalcitonin and C-reactive protein as markers of infection in systemic lupus erythematosus: the controversy continues. Lupus. 2018 Jan 1:961203318777101. doi: 10.1177/096120331877710

14. Ospina FE, Echeverri A, Zambrano D, et al. Distinguishing infections vs flares in patients with systemic lupus erythematosus. Rheumatology. 2017;56(Suppl 1):i46-i54. doi: 10.1093/rheumatology/kew340

15. Eberhard OK, Haubitz M, Brunkhorst FM, et al. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody associated vasculitis) and invasive bacterial infection. Arthritis Rheum. 1997;40(7):1250-6. doi: 10.1002/1529-0131(199707)40:7<1250::AIDART9>3.0.CO;2-A

16. Schwenger V, Sis J, Breitbart A, et al. CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection. 1998;26(5):274-6. doi: 10.1007/BF02962246

17. Scire CA, Cavagna L, Perotti C, et al. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol. 2006;24(2):123-8.

18. Chen DY, Chen YM, Ho WL, et al. Diagnostic value of procalcitonin for differentiation between bacterial infection and noninfectious inflammation in febrile patients with active adult-onset Still's disease. Ann Rheum Dis. 2009;68(6):1074-5. doi: 10.1136/ard.2008.098335

19. Вельков ВВ. Пресепсин – эффективный биологический мар- кер для диагностики сепсиса и мониторинга системных ин- фекций. Здоровье. Медицинская экология. Наука. 2016;1(64):4-21 [Vel'kov VV. Presepsin is an effective biological marker for diagnosing sepsis and monitoring systemic infections. Zdorov'e. Medicinskaya ekologiya. Nauka. 2016;1(64):4-21 (In Russ.)].

20. Tsuji S, Kitatoube A, Kikuchi-Taura A, et al. Elevated soluble CD14-subtype (PRESEPSIN; P-SEP) levels in rheumatoid arthritis (RA) patients with bacterial infection. Mod Rheumatol. 2017;27(4):718-20. doi: 10.1080/14397595.2016.1246119

21. Oguro E, Tsuji S, Kuzuya K, et al. Serum presepsin as a novel biomarker for bacterial infection in rheumatoid arthritis patients treated with tocilizumab. Ann Rheum Dis. 2018;77(Suppl 2):296. doi: 10.1136/annrheumdis-2018-eular.3914

22. Tsujimoto K, Hata A, Fujita M, et al. Presepsin and procalcitonin as biomarkers of systemic bacterial infection in patients with rheumatoid arthritis. Int J Rheum Dis. 2018;21(7):1406-13. doi: 10.1111/1756-185X.12899

23. Tanimura S, Fujieda Y, Kono M, et al. Clinical significance of plasma presepsin levels in patients with systemic lupus erythematosus. Modern Rheumatol. 2018;28(5):865-71. doi: 10.1080/14397595.2017

24. Yeh CF, Wu CC, Liu SH, Chen KF. Comparison of the accuracy of neutrophil CD64, procalcitonin, and C-reactive protein for sepsis identification: a systematic review and meta-analysis. Ann Intensive Care. 2019 Jan 8;9(1):5. doi: 10.1186/s13613-018-0479-2

25. Echeverri A, Naranjo-Escobar J, Posso-Osorio I, et al. Neutrophil CD64 expression, procalcitonin and presepsin are useful to differentiate infections from flares in SLE patients with SIRS. Lupus. 2018;27(7):1130-9. doi: 10.1177/0961203318763740

26. Feng M, Zhang SL, Liang ZJ, et al. Peripheral neutrophil CD64 index combined with complement, CRP, WBC count and B cells improves the ability of diagnosing bacterial infection in SLE. Lupus. 2019 Feb 2:961203319827646. doi: 10.1177/0961203319827646

27. Zhang J, She D, Feng D, et al. Dynamic changes of serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) reflect sepsis severity and can predict prognosis: a prospective study. BMC Infect Dis. 2011;11:53. doi: 10.1186/1471-2334-11-53

28. Wu Y, Wang F, Fan X, et al. Accuracy of plasma sTREM-1 for sepsis diagnosis in systemic inflammatory patients: a systematic review and meta-analysis. Crit Care. 2012;16(6):R229. doi: 10.1186/cc11884

29. Kim J, Koh JK, Lee EY, et al. Serum levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and pentraxin 3 (PTX3) as markers of infection in febrile patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2009 Sep-Oct;27(5):773-8.

30. Molad Y, Pokroy-Shapira E, Kaptzan T, et al. Serum soluble triggering receptor on myeloid cells-1 (sTREM-1) is elevated in systemic lupus erythematosus but does not distinguish between lupus alone and concurrent infection. Inflammation. 2013;36(6):1519-24. doi: 10.1007/s10753-013-9694-z

31. Ajmani S, Singh H, Chaturvedi S, et al. Utility of neutrophil CD64 and serum TREM-1 in distinguishing bacterial infection from disease flare in SLE and ANCA-associated vasculitis. Clin Rheumatol. 2018 Nov 16. doi: 10.1007/s10067-018-4334-5

32. Lin CH, Hsieh SC, Keng LT, et al. Prospective Evaluation of Procalcitonin, Soluble Triggering Receptor Expressed on Myeloid Cells-1 and C-Reactive Protein in Febrile Patients with Autoimmune Diseases. PLoS One. 2016;11(4):e0153938. doi: 10.1371/journal.pone.0153938

33. Pliyev BK, Menshikov MY. Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis. Inflammation. 2010;33(1):1-9. doi: 10.1007/s10753-009-9152-0

34. Zaitoon YA, Shehab AA, Mohamed NA. Plasma Soluble Urokinase Plasminogen Activator Receptor Levels in Systemic Lupus Erythematosus Patients. Egypt J Immunol. 2018 Jan;25(1):35-43.

35. Kurtipek GS, Kesli R, Tuncez Akyü rek F, et al. Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in psoriasis patients and correlation with disease severity. Acta Dermatovenerol Alp Pannonica Adriat. 2015;24(4):73-5. doi: 10.15570/actaapa.2015.19

36. Legany N, Toldi G, Distler JH, et al. Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis. Clin Chem Lab Med. 2015 Oct;53(11):1799-805. doi: 10.1515/cclm-2015-0079

37. Xiao Y, Luo H, Zhou B, et al. Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy. Rheumatol Int. 2017 Apr;37(4):585-92. doi: 10.1007/s00296-016-3609-x

38. Александрова ЕН, Новиков АА, Насонов ЕЛ. Современные стандарты лабораторной диагностики ревматических заболеваний. Москва; 2012. 63 с. [Aleksandrova EN, Novikov AA, Nasonov EL. Sovremennye standarty laboratornoy diagnostiki revmaticheskih zabolevaniy [Modern standards for laboratory diagnosis of rheumatic diseases]. Moscow; 2012. 63 p. (In Russ.)].

39. Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol. 2017;13(7):399-409. doi: 10.1038/nrrheum.2017.83

40. Holub M, Dzupova O, Ruzkova M, et al. Selected Biomarkers Correlate with the Origin and Severity of Sepsis. Mediators Inflamm. 2018 Mar 27;2018:7028267. doi: 10.1155/2018/7028267

41. Zhang Y, Khalid S, Jiang L. Diagnostic and predictive performance of biomarkers in patients with sepsis in an intensive care unit. J Int Med Res. 2019;47(1):44-58. doi: 10.1177/0300060518793791

42. Iwase S, Nakada TA, Hattori N, et al. Interleukin-6 as a diagnostic marker for infection in critically ill patients: A systematic review and meta-analysis. Am J Emerg Med. 2019;37(2):260-5. doi: 10.1016/j.ajem.2018.05.040


Для цитирования:


Белов Б.С., Тарасова Г.М., Муравьева Н.В. Роль биомаркеров в диагностике бактериальных инфекций при ревматических заболеваниях. Научно-практическая ревматология. 2019;57(3):333-338. https://doi.org/10.14412/1995-4484-2019-333-338

For citation:


Belov B.S., Tarasova G.M., Muravyeva N.V. Role of biomarkers in the diagnosis of bacterial infections in rheumatic diseases. Rheumatology Science and Practice. 2019;57(3):333-338. (In Russ.) https://doi.org/10.14412/1995-4484-2019-333-338

Просмотров: 22


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)